CIAE放射性药物和标记化合物的发展  

Development of Radiopharmaceutical and Radiolabeled Compound at CIAE

作　　者：樊彩云[1] 韩世泉[1] 罗志福[1] FAN Caiyun;HAN Shiquan;LUO Zhifu(Department of Isotope,China Institute of Atomic Energy,Beijing 102413,China)

机构地区：[1]中国原子能科学研究院同位素研究所,北京102413

出　　处：《原子能科学技术》2020年第S01期185-193,共9页Atomic Energy Science and Technology

摘　　要：本文回顾了中国原子能科学研究院(CIAE,简称原子能院)建院70年以来在放射性药物方向的发展历程,重点介绍了原子能院放射性药物、放射性标记化合物及放射免疫分析研究、开发和生产技术方面的发展,历年来的主要产品以及取得的主要成绩,并提出了今后原子能院放射性药物领域发展的主要方向。The development of radiopharmaceuticals in the last seventy years since the establishment of CIAE was reviewed.The technologies of research,development and production on radiopharmaceuticals,radiolabeled compounds and radioimmunoassay along with main products and achievements were described.Based on the above analysis,the main developmental directions in the future are put forward.

关 键 词：放射性药物 放射性标记化合物 放射免疫分析 

分 类 号：TL364.5[核科学技术—核技术及应用]